5-day/5-drug myeloablative outpatient regimen for resistant neuroblastoma
Brian H. Kushner(Memorial Sloan Kettering Cancer Center), N K Cheung(Memorial Sloan Kettering Cancer Center), Ellen M. Basu(Memorial Sloan Kettering Cancer Center), Stephen S. Roberts(Memorial Sloan Kettering Cancer Center), Kim Kramer(Memorial Sloan Kettering Cancer Center), Shakeel Modak(Memorial Sloan Kettering Cancer Center)
Cited by 6
Related Papers
Ganglioside GD2 specific monoclonal antibody 3F8: a phase I study in patients with neuroblastoma and malignant melanoma.
|Journal of Clinical Oncology|1987|417
Augmentation of antibody dependent cell mediated cytotoxicity following in vivo therapy with recombinant interleukin 2.
|PubMed|1990|156
Entrectinib in children and young adults with solid or primary CNS tumors harboring <i>NTRK</i>, <i>ROS1</i>, or <i>ALK</i> aberrations (STARTRK-NG)
|Neuro-Oncology|2022|136
Phagocytosis of tumor cells by human monocytes cultured in recombinant macrophage colony-stimulating factor.
|The Journal of Experimental Medicine|1990|126